This CYP17A1 inhibitor is used to treat androgen-dependent diseases like castration-resistant prostate cancer [30] and has been used to efficiently normalize excess circulating androgen levels in CAH patients [31]. This evidence concerns the gene CYP17A1 and congenital adrenal hyperplasia.